Combating Lassa Fever in West African Sub-Region: Progress, Challenges, and Future Perspectives

Area of Science:

• Virology
• Infectious Diseases
• Public Health

Background:

• Lassa fever (LF) is a significant public health threat in West Africa, caused by the Lassa virus (LASV).
• Limited treatment options and the absence of an approved vaccine contribute to high mortality rates in endemic regions.
• The zoonotic transmission cycle involves rodents, posing challenges for disease control.

Purpose of the Study:

• To review the transmission, pathogenicity, and current treatment landscape of Lassa fever.
• To identify challenges and explore novel therapeutic targets for Lassa virus (LASV).
• To highlight the potential of targeting the LASV nucleoprotein (NP) for drug development.

Main Methods:

• This study is a narrative review of existing literature on Lassa fever.
• It explores the genetic diversity of LASV strains and their immune evasion mechanisms.
• Investigates the role of the LASV nucleoprotein (NP) in the viral life cycle.

Main Results:

• Genetic diversity and immune evasion by LASV strains present major hurdles for vaccine and therapeutic development.
• The LASV nucleoprotein (NP) is identified as a critical target due to its role in viral replication.
• In silico and computational bioinformatics approaches, along with drug repurposing (e.g., ribavirin), show potential.

Conclusions:

• Understanding LASV's molecular mechanisms, including immune evasion, is crucial for developing effective treatments and vaccines.
• Inhibitors targeting the LASV nucleoprotein (NP) represent a promising therapeutic avenue.
• Integrated strategies involving preventive measures, vaccine development, target validation, and drug repurposing are essential for LF management.